Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 plus anlotinib and chemotherapy in EGFR-TKI resistant advanced NSCLC
ChiCTR2600120704Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Bengbu Medical University
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QL1706 in non-small cell lung cancer (NSCLC), sponsored by First Affiliated Hospital of Bengbu Medical University. Primary endpoint: Progression-Free Survival. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600120704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600120704.